OncoMatch/Clinical Trials/NCT06535893
Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer
Is NCT06535893 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including TN and TN-1 for breast cancer.
Treatment: TN · TN-1 — Randomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06535893 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage II or III is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages